Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients

Phio Pharmaceuticals Corp PHIO said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762.
Phio is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells.
PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorally in preclinical models, PH-762 primes an anti-tumor immune response and inhibits tumor growth.
Related: Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells.
Phio is currently conducting a Phase 1b clinical trial of PH-762 for advanced melanoma.
Phio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on cutaneous squamous cell carcinoma and other selected cutaneous malignancies.
Price Action: PHIO shares are up 4.08% at $0.39 during the premarket session on the last check Thursday.